<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3022">
  <stage>Registered</stage>
  <submitdate>9/12/2010</submitdate>
  <approvaldate>9/12/2010</approvaldate>
  <nctid>NCT01258205</nctid>
  <trial_identification>
    <studytitle>Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease, and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20090519</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 139

Experimental: Part B - One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.

Experimental: Part A - Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.


Treatment: drugs: AMG 139
Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety &amp; tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139</outcome>
      <timepoint>36 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Characterization of the pharmacokinetic (PK) parameters (AUCtau, Cmax, tmax) for AMG 139 after multiple IV and SC dose administrations in healthy subjects and subjects with mild to severe CD</outcome>
      <timepoint>36 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Part A - Healthy Subjects:

          -  Healthy male or female of non-reproductive potential subjects between 18 to 45
             years-of-age

          -  Body mass index (BMI) between 18 and 32 kg/m2

          -  Normal or clinically acceptable physical examination, clinical laboratory values, and
             ECG

          -  Additional inclusion criteria apply

        Part B - Crohn's Subjects:

          -  Male or female subjects with CD between 18 to 55 years-of-age

          -  Body mass index (BMI) between 18 and 32 kg/m2

          -  Normal or clinically acceptable physical examination (PE), clinical laboratory values,
             and ECG; clinically acceptable PE includes evidence of mild to severe CD

          -  Diagnosis of ileal or ileo-colonic CD for a minimum of 6 months

          -  Mild to severe CD defined by a Crohn's Disease Activity Index (CDAI) score equal to or
             greater than 180 and equal to or less than 450

          -  Elevated fecal calprotectin and CRP

          -  Additional inclusion criteria apply</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Parts A - Healthy Subjects:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  Recent or on-going infection(s)

          -  Underlying condition(s) that predisposes the subject to infections

          -  History of malignancy of any type

          -  Additional exclusion criteria apply

        Part B only - Crohn's Subjects:

          -  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluation, procedures or completion;

          -  Recent or on-going infection(s)

          -  Underlying condition(s) that predisposes the subject to infections

          -  History of malignancy of any type

          -  Additional exclusion criteria apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>28/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>48</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/02/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC</recruitmentstate>
    <hospital>QPharm Pty Limited - Herston</hospital>
    <hospital>Clinical Medical and Analytical eXellence CMAX - Adelaide</hospital>
    <hospital>Centre for Clinical Studies (Alfred) - Prahran</hospital>
    <postcode>4029 - Herston</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety and tolerability of AMG 139 following
      multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in
      subjects with mild to severe Crohn's disease (CD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01258205</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Carl Gommoll, MS</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>